QSAR and docking based semi-synthesis and in vitro evaluation of 18 β-glycyrrhetinic acid derivatives against human lung cancer cell line A-549

Medicinal Chemistry

Volumn 9, Issue 8, 2013, Pages 1073-1084

  Yadav, Dharmendra Kumar ^a   Kalani, Komal ^a   Khan, Feroz ^a   Srivastava, Santosh Kumar ^a  

^a CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

Author keywords

18 glycyrrhetinic acid; Docking; Drug likeness; Human lung cancer (A 549); In vitro cytotoxicity; QSAR

Indexed keywords

18 BETA GLYCYRRHETINIC ACID DERIVATIVE; AMINE; ANTINEOPLASTIC AGENT; ASPARTIC ACID; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLUTAMIC ACID; GLYCERYL TRINITRATE; GLYCYRRHETINIC ACID DERIVATIVE; HYDROXYL GROUP; LEUCINE; METHIONINE; PACLITAXEL; PDB 2JIU; PHENYLALANINE; THREONINE; UNCLASSIFIED DRUG; VALINE; 18ALPHA-GLYCYRRHETINIC ACID; GLYCYRRHETINIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CANCER CELL CULTURE; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL STRUCTURE; CYTOTOXICITY; DEVELOPMENTAL TOXICITY; DIPOLE; DRUG ABSORPTION; DRUG ANALYSIS; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG EXCRETION; DRUG ISOLATION; DRUG METABOLISM; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; FRACTIONATION; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; INTESTINE MUCOSA PERMEABILITY; KIDNEY CLEARANCE; LIPOPHILICITY; LUNG CANCER; MOLECULAR DOCKING; MOLECULAR MODEL; MOLECULAR WEIGHT; MUTAGENIC ACTIVITY; MUTAGENICITY; NUCLEOPHILICITY; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; PREDICTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RANDOMIZATION; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; SKIN PERMEABILITY; STEREOCHEMISTRY; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GLYCYRRHETINIC ACID; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84890308448     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406411309080009     Document Type: Article

References (30)

1. Girard, M. P.; Katz, J. M.; Pervikov, Y.; Hombach, J.; Tam, J. S. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011. Vaccine., 2011, 29, 7579-86.
2. Harvey, A. L. Natural products as a screening resource. Curr. Opin. Chem. Biol., 2007, 11, 480-484.
3. Newman, D. J.; Cragg, G. M.; Snader, K. M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 2003, 66, 1022-1037.
4. Sparg, S. G.; Light, M. E.; van Staden, J. Biological activities and distribution of plant saponins. J. Ethnopharmacol., 2004, 94, 219-43.
5. Riahi, S.; Pourbasheer, E.; Dinarvand, R.; Ganjali, M. R.; Norouzi, P. QSAR study of 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide as PARP inhibitors for treatment of cancer. Chem. Biol. Drug Des., 2008, 72, 575-84.
6. Sun, W.; Peng, W.; Li, G.; Jiang, T. Design, synthesis, and sustained- release property of 1, 3-cyclic propanyl phosphate ester of 18beta- glycyrrhetinic acid. Chem. Biol. Drug Des., 2011, 77, 206-11.
7. Jung, H. J.; Nam, J. H.; Choi, J.; Lee, K. T.; Park, H. J. 19Alphahydroxyursane- type triterpenoids: antinociceptive anti-inflammatory principles of the roots of Rosa rugosa. Biol. Pharm. Bull., 2005, 28, 101-4.
8. Ikeda, T.; Yokomizo, K.; Okawa, M.; Tsuchihashi, R.; Kinjo, J.; Nohara, T.; Uyeda, M. Anti-herpes virus type 1 activity of oleanane-type triterpenoids. Biol. Pharm. Bull., 2005, 28, 1779-81.
9. Riahi, S.; Pourbasheer, E.; Dinarvand, R.; Ganjali, M. R.; Norouzi, P. QSAR study of 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide as PARP inhibitors for treatment of cancer. Chem. Biol. Drug Des., 2008, 72, 575-84.
10. Csuk, R.; Schwarz, S.; Kluge, R.; Strohl, D. Synthesis and biological activity of some antitumor active derivatives from glycyrrhetinic acid. Eur. J. Med. Chem., 2010, 45, 5718-5723.
11. Asl, M. N.; Hosseinzadeh, H. Review of pharmacological effects of Glycyrrhiza sp and its bioactive compounds. Phytotherapy Research., 2008, 22, 709-724.
12. Wang, Z. Y.; Nixon, D. W. Licorice and cancer. Nutr. Cancer, 2001, 39, 1-11.
13. Logashenko, E. B.; Salomatina, O. V.; Markov, A. V.; Korchagina, D. V.; Salakhutdinov, N. F.; Tolstikov, G. A.; Vlassov, V. V.; Zenkova, M. A. Synthesis and pro-apoptotic activity of novel glycyrrhetinic acid derivatives. ChemBiochem., 2011, 12, 784-94.
14. Li, J. F.; Zhao, Y.; Cai, M. M.; Li, X. F.; Li, J. X. Synthesis and evaluation of a novel series of heterocyclic oleanolic acid derivatives with anti-osteoclast formation activity. Eur. J. Med. Chem., 2009, 44, 2796-2806.
15. Gupta, S.; Kalani, K.; Saxena, M.; Srivastava, S. K.; Agarwal, S. K.; Suri, N.; Saxena, A. K. Cytotoxic Evaluation of Semisynthetic Ester and Amide Derivatives of Oleanolic Acid. Nat. Prod. Commun., 2010, 5, 1567-1570.
16. Yadav, D. K.; Khan, F., QSAR, docking and ADMET studies of camptothecin derivatives as inhibitors of DNA topoisomerase-I. J. Chemometrics., 2013, 25 (1-2), 21-33.
17. Kalani, K.; Yadav, D. K.; Khan, F.; Srivastava, S. K.; Suri, N. Pharmacophore, QSAR, and ADME based semisynthesis and in vitro evaluation of ursolic acid analogs for anticancer activity. J. Mol. Model., 2012, 18, 3389-413.
18. Tao, L. Y.; Zhang, J. Y.; Liang, Y. J.; Chen, L. M.; Zhen, L. S.; Wang, F.; Mi, Y. J.; She, Z. G.; To, K. K.; Lin, Y. C.; Fu, L. W. Anticancer effect and structure-activity analysis of marine products isolated from metabolites of mangrove fungi in the South China Sea. Mar. Drugs., 2010, 8, 1094-105.
19. Aibin Wu, J. L., Shaoxiong Qin and Ping Mei. Derivatives of 5-nitro-1H-benzo[de]isoquinoline-1,3(2H)-dione: design, synthesis, and biological activity. Monatsh Chem., 2010, 141, 95-99.
20. Yadav, D. K.; Meena, A.; Srivastava, A.; Chanda, D.; Khan, F.; Chattopadhyay, S. K. Development of QSAR model for immunomodulatory activity of natural coumarinolignoids. Drug Des. Devel. Ther., 2010, 4, 173-86.
21. Meena, A.; Yadav, D. K.; Srivastava, A.; Khan, F.; Chanda, D.; Chattopadhyay, S. K. In silico exploration of anti-inflammatory activity of natural coumarinolignoids. Chem. Biol. Drug Des., 2011, 78, 567-79.
22. Yadav, D. K.; Khan, F.; Negi, A. S. Pharmacophore modeling, molecular docking, QSAR, and in silico ADMET studies of gallic acid derivatives for immunomodulatory activity. J. Mol. Model., 2012, 18, 2513-25.
23. Umar, S.; Singh, V.; Tiwari, M. QSAR modeling of the inhibition of reverse transcriptase enzyme with benzimidazolone analogs. Med. Chem. Res., 2011, 20, 1530-1541.
24. Kumar, S.; Singh, V.; Tiwari, M. Quantitative structure activity relationship studies of sulfamide derivatives as carbonic anhydrase inhibitor: As antiglaucoma agents. Med Chem., 2007, 3, 379-386.
25. Maurya, A.; Khan, F.; Bawankule, D. U.; Yadav, D. K.; Srivastava, S. K. QSAR, docking and in vivo studies for immunomodulatory activity of isolated triterpenoids from Eucalyptus tereticornis and Gentiana kurroo. Eur. J. Pharm. Sci., 2012, 47, 152-61.
26. Kalani, K.; Kushwaha, V.; Verma, R.; Murthy, P. K.; Srivastava, S. K. Glycyrrhetinic acid and its analogs: A new class of antifilarial agents. Bioorg. Med. Chem. Lett., 2013, 23, 2566-2570.
27. Shen, M.; Xiao, Y.; Golbraikh, A.; Gombar, V. K.; Tropsha, A. Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. J. Med. Chem., 2003, 46, 3013-20.
28. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 1990, 82, 1107-12.
29. Li, S.; Qiu, Y.; Zhang, S.; Gao, Y. Enhanced transdermal delivery of 18beta-glycyrrhetic acid via elastic vesicles: in vitro and in vivo evaluation. Drug Dev. Ind. Pharm., 2012, 38, 855-65.
30. Andersen, F. A. Final report on the safety assessment of Glycyrrhetinic Acid, Potassium Glycyrrhetinate, Disodium Succinoyl Glycyrrhetinate, Glyceryl Glycyrrhetinate, Glycyrrhetinyl Stearate, Stearyl Glycyrrhetinate, Glycyrrhizic Acid, Ammonium Glycyrrhizate, Dipotassium Glycyrrhizate, Disodium Glycyrrhizate, Trisodium Glycyrrhizate, Methyl Glycyrrhizate, and Potassium Glycyrrhizinate. Int. J. Toxicol., 2007, 26, 79-112.